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PCR detected EIAV nucleic acid in 31/56 AGID positive samples,
while 108/109 AGID negative samples tested negative by iiRT-
PCR. Total agreement was 84.24%. When whole blood samples
were evaluated, a total of 16 iiRT-PCR positive and 15 iiRT-PCR
negative out of 31 AGID positive samples were obtained. Addi-
tionally, EIAV nucleic acid was not detected in 25 AGID negative
samples .Total agreement was 73.21% for this sample type. When
evaluating the accuracy of EIAV iiRT-PCR and qPCR, 28/165 and
130/165 buffy coat samples tested positive and negative by both
assays, respectively. Five iiRT-PCR positive samples were negative
by qPCR and two qPCR positive samples were negative by iiRT-
PCR. Thus, EIAV iiRT-PCR showed more than 95% agreement with
qPCR results. It has been demonstrated that the absence of clinical
signs is correlated with very low, frequently undetectable
viremia. Therefore, EIAV iiRT-PCR appears to be a promising tool
to identify infected horses including those experiencing low
infectivity titers in blood. Furthermore, as initial EIAV replication
rates are frequently high, recently infected equids pose a
considerable transmission risk long before seroconversion. In our
study, a horse was determined seronegative by AGID, but was
identiﬁed as EIAV infected by iiRT-PCR. Thus, EIAV iiRT-PCR could
be considered as an alternative diagnostic tool in the imple-
mentation of control strategies during an EIA outbreak in the low
prevalence area of our country.
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Equine arteritis virus (EAV) is the cause of equine viral arteritis,
a systemic viral disease of equids that is characterized by signsTable 1
Diagnostic performance of previous EAV ELISAs
Assay format, number sera tested Diagnostic sensitivity Diagnostic speciﬁcity Reference
Indirect ELISA (gp5+N+M), 187 92.3, 57.1% 100% J Virol Methods 76:127-37
Indirect ELISA (peptide, N and replicase), 200 99% 71% J Virol Methods 73:175-83
Indirect ELISA (WV), 839 87.5% 98.9% J Vet Med Sci 60:1043-5
Indirect ELISA (gp5), 1500 99.6% 90.1% J Virol Methods 54:1-13
Indirect ELISA (WV), 46 96% 26% Equin Vet J 40(2):182-3
Competitive blocking ELISA (M), 100 86% 100% CIMID. 26:251-60
Indirect ELISA (gp5), 800 96.75% 95.8% J Virol Methods 90:167-83
Competitive blocking ELISA (gp5), 675 90.7% 99% CJVR;64:38-43of respiratory disease, abortion, and infrequently, death in
young foals. OIE deﬁnes a horse as seropositive if its EAV virus
neutralization (VN) antibody titer is 1:4. The VN test can take
up to 72 hours to complete and requires certain laboratory fa-
cilities, equipment, and technical expertise to perform. Non-
viral cytotoxicity of sera from some horses vaccinated with
certain equine herpesvirus-1 vaccines can interfere with
interpretation of the test. Inter-laboratory variation in VN re-
sults due to variables such as reference virus used, type and cell
passage history has been reported. For these reasons an alter-
native serologic test is desirable, but none of the previously
reported ELISA tests (Table 1) have shown equivalent sensitivityand speciﬁcity compared to the VN test. With the aim of pro-
ducing a simpler and faster alternative to the OIE-prescribed
test, a cELISA was developed using EAV gp5-speciﬁc non-
neutralizing monoclonal antibody (MAb) 17B7. This cELISA was
validated with diverse sera (n¼2469) against the VN test. It had
a diagnostic sensitivity of 95.5% and a diagnostic speciﬁcity of
99.8% (JVDI. 25:182-8). The MAb-17B7 cELISA was further
validated in three EAV-testing laboratories including one OIE-
reference and two AAVLD-accredited laboratories: These
conﬁrmed a test sensitivity of 99.5% and a speciﬁcity of 98.2%
(JVDI 25:727-35). As part of test validation, the following ﬁve
additional analyses were satisfactorily performed according to
the OIE-recommended validation protocol: 1. the primary assay
was calibrated with the OIE approved reference serum panel for
EVA, 2. repeatability of the assay was evaluated within and
between runs, 3. analytical speciﬁcity was evaluated using sera
speciﬁc for selected equine viruses, 4. analytical sensitivity was
evaluated with sera collected from horses vaccinated with the
modiﬁed live virus vaccine against EVA (Arvac®, Zoetis Animal
Health), and 5. Duration of the positive cELISA antibody was
evaluated following EVA vaccination. The analytical sensitivity
of the new cELISA was comparable to the VN test in that it
detected EAV-speciﬁc antibody as early as 6 days post-vacci-
nation. The duration of EAV-speciﬁc antibody detection by
cELISA was over six years post-vaccination. Based on the data
obtained, signiﬁcant correlation was demonstrated between
the VN test and cELISA results (r2¼0.79, P<0.0001). The cELISA
was further improved using EAV puriﬁed by anion-exchange
membrane chromatography (JVDI accepted). This enhanced
cELISA was validated using diverse sera (n¼3255) at the
Maxwell H. Gluck Equine Research Center. The relative sensi-
tivity and speciﬁcity of this assay against a group of ﬁeld sera
(n¼1851) was 99.6% (95% CI 99.4-100.0) and 98.7% (95% CI 98.3,
99.6), respectively, compared to the VN test (manuscript sub-
mitted). This rapid, highly sensitive and speciﬁc cELISA com-
pares very favorably to the VN test. It is USDA licensed and
should facilitate screening of horses intended for international
movement.045
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